Price T Rowe Associates Inc. MD Sells 61,634 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Price T Rowe Associates Inc. MD decreased its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 2.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 3,007,327 shares of the company's stock after selling 61,634 shares during the quarter. Price T Rowe Associates Inc. MD owned 3.96% of Nurix Therapeutics worth $56,659,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% in the 4th quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares in the last quarter. Summit Investment Advisors Inc. lifted its holdings in shares of Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after purchasing an additional 877 shares during the period. ADAR1 Capital Management LLC acquired a new position in Nurix Therapeutics during the fourth quarter worth $207,000. KLP Kapitalforvaltning AS acquired a new stake in Nurix Therapeutics in the fourth quarter valued at $209,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Nurix Therapeutics in the 4th quarter valued at about $226,000.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 5,825 shares of Nurix Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $14.49, for a total transaction of $84,404.25. Following the completion of the transaction, the chief financial officer now owns 33,724 shares in the company, valued at approximately $488,660.76. This trade represents a 14.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Gwenn Hansen sold 3,377 shares of the stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $11.50, for a total transaction of $38,835.50. Following the sale, the insider now owns 61,516 shares in the company, valued at $707,434. The trade was a 5.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 17,838 shares of company stock valued at $221,500. 7.40% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on NRIX shares. JPMorgan Chase & Co. decreased their price target on shares of Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a research note on Wednesday, January 29th. Needham & Company LLC restated a "buy" rating and issued a $27.00 price target on shares of Nurix Therapeutics in a report on Tuesday. HC Wainwright restated a "buy" rating and issued a $36.00 price target on shares of Nurix Therapeutics in a report on Wednesday, April 2nd. Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a research report on Wednesday, April 9th. Finally, Leerink Partners started coverage on Nurix Therapeutics in a research report on Monday, March 17th. They issued a "market perform" rating and a $16.00 target price on the stock. Three research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $30.44.

Nurix Therapeutics Price Performance

NRIX stock traded up $0.11 during midday trading on Friday, hitting $11.27. The company's stock had a trading volume of 599,966 shares, compared to its average volume of 887,812. The company's fifty day moving average price is $12.13 and its 200 day moving average price is $18.08. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56. The stock has a market capitalization of $859.18 million, a P/E ratio of -3.90 and a beta of 2.23.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last released its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to analyst estimates of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the prior year, the company posted ($0.76) earnings per share. Equities analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.